News - Impax Laboratories, Newron Pharma

Filter

Popular Filters

1 to 25 of 38 results

Safinamide marketing application submitted to Swissmedic

07-04-2014

Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

Markets & MarketingNeurologicalNewron PharmaNorthern EuropePharmaceuticalRegulationsafinamideZambon

Impax and DURECT in $63 million deal for Eladur pain patch

07-01-2014

US specialty drugmaker Impax Laboratories has entered into an agreement with fellow USA-based DURECT…

DurectEladurGlobalImpax LaboratoriesLicensingNeurologicalPharmaceutical

Patent expiries will push Parkinson’s drug market lower by 2019

17-12-2013

Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s disease (PD)…

GlobalImpax LaboratoriesMarkets & MarketingNeurologicalNewron PharmaPatentsPharmaceuticalpimavanserinRytarysafinamide

Newron and Zambon file for EU approval of Parkinson’s drug safinamide

09-12-2013

Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

EuropeNeurologicalNewron PharmaNorth AmericaPharmaceuticalRegulationsafinamideZambon

Acura Pharma settles with Par and Impax over Oxecta

Acura Pharma settles with Par and Impax over Oxecta

11-10-2013

US specialty pharma firm Acura Pharmaceuticals saw its shares leap as much as 28% after it said that…

Acura PharmaceuticalsGenericsImpax LaboratoriesLicensingNeurologicalNorth AmericaOxectaPar PharmaceuticalPatents

Generic versions of Trilipix debut in USA; Mylan sued by UCB

16-07-2013

Impax Laboratories (Nasdaq: IPXL) today announced yesterday (July 15) that it is commencing shipment…

AbbVieCardio-vascularGenericsImpax LaboratoriesLegalMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaPatentsTripilixUCBVimpat

Impax Labs confirms patent challenge to Pfizer/UCB's Toviaz

04-07-2013

US specialty drugmaker Impax Laboratories (Nasdaq: IPXL) yesterday confirmed that it has initiated a…

Gastro-intestinalsGenericsImpax LaboratoriesNorth AmericaPatentsPfizerToviazUCB

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

19-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

Impax launches authorized generic of Zomig, as Mylan debuts copy of Tricor in USA

20-05-2013

US drugmaker Impax Laboratories (Nasdaq: IPXL) says that its generics division, Global Pharmaceuticals,…

AbbVieAstraZenecaCardio-vascularGenericsImpax LaboratoriesMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaTricorZomig

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug

30-04-2013

US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Shire settles with Impax on Adderall XR authorized generic; initiates Ph III ABH001 study

10-02-2013

Ireland-based drugmaker Shire (LSE: SHP) says it has settled all pending litigation with Impax Laboratories…

ABH001Adderall XRDermatologicalsGenericsImpax LaboratoriesLegalNeurologicalNorth AmericaPharmaceuticalResearchShire

Another stumbling block for Impax Pharma's Rytary

22-01-2013

Impax Pharmaceuticals, the branded products division of Impax Laboratories (Nasdaq: IPXL), revealed on…

GlaxoSmithKlineImpax LaboratoriesNeurologicalNorth AmericaPharmaceuticalProductionRegulationRytary

Endo fails in FDA law suit to stop generic Opana ER in USA; Mylan settles with Orion

21-12-2012

The US District Judge Reggie Walton, of the District Court for the District of Columbia, has dismissed…

ActavisComtanEndo PharmaceuticalsGenericsImpax LaboratoriesLegalMylan LaboratoriesNeurologicalNorth AmericaOpana ERPharmaceutical

Impax in deal with Perrigo; Cipla eyes South Africa acquisition

22-11-2012

Impax Laboratories (Nasdaq: IPXL) said yesterday that it plans to collaborate with fellow US drugmaker…

CiplaCipla MedproGenericsImpax LaboratoriesMarkets & MarketingMergers & AcquisitionsNorth AmericaPerrigoResearchRest of the World

Impax Labs and Teva settle Concerta litigation with J&J units

17-09-2012

USA-based Impax Laboratories (Nasdaq: IPXL) and the US unit of Israel generics giant Teva Pharmaceutical…

ALZA CorpConcertaGenericsImpax LaboratoriesJanssenJohnson & JohnsonNeurologicalNorth AmericaPatentsTeva Pharmaceutical Industries

Impax Labs settles with Genzyme over Renvela and Renagel generics

05-09-2012

USA-based Impax Laboratories (Nasdaq: IPXL) says it has reached agreement with French drug major Sanofi's…

GenzymeImpax LaboratoriesPatentsPharmaceuticalRenagelRenvelaSanofi

Impax and Tolmar enter generic drug distribution deal

27-06-2012

US generic drugmaker Impax Laboratories (Nasdaq: IPXL) has entered into a collaboration with contract…

GenericsImpax LaboratoriesLicensingMarkets & MarketingResearchTolmar

Newron executes safinamide deal with Zambon; new Ph III data; management changes

15-05-2012

In what was a busy news day for Italian drug developer Newron Pharmaceuticals SpA (SIX: NWRN), the company…

FinancialLicensingManagementNeurologicalNewron PharmaPharmaceuticalResearchsafinamideZambon

Mylan debuts Lescol copy; Impax challenges Gralise patent

16-04-2012

US generic drug major Mylan (Nasdaq: MYL) revealed last Friday that it has begun shipping its generic…

Cardio-vascularDepomedGenericsGraliseImpax LaboratoriesLescolMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaNovartisPatentsRegulation

Newron licenses safinamide to Zambon for EU and USA

09-04-2012

Italian drug developer Newron Pharmaceuticals (SIX: NWRN) says that it has signed a strategic collaboration…

LicensingMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalsafinamideZambon

1 to 25 of 38 results

Back to top